genryzon®
Brand Name: Ngenla® (Printed as ggenyzon® / genryzon® in regional branding)
Manufacturer: Pfizer
Composition: Somatrogon
Product Description
Medical Info
Ngenla is a long-acting recombinant human growth hormone therapy manufactured by Pfizer, containing the active substance Somatrogon. Formulated as a 24 mg/ml solution inside a multi-dose pre-filled pen, it is engineered as a weekly subcutaneous injection rather than a daily regimen. This drug functions by replacing endogenous growth hormone to stimulate skeletal linear growth, tissue expansion, and cellular metabolism. It is explicitly indicated for the long-term treatment of pediatric patients aged three years and older who experience growth failure due to growth hormone deficiency. Administration must be clinically supervised.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
